Zobrazeno 1 - 10
of 109 608
pro vyhledávání: '"non‐small‐cell lung cancer"'
Autor:
Harry Etienne, MD, PhD, Bianca Battilana, MM, Jonathan Spicer, MD, PhD, Raphael S. Werner, MD, MSc, Isabelle Opitz, MD
Publikováno v:
JTCVS Open, Vol 19, Iss , Pp 338-346 (2024)
Externí odkaz:
https://doaj.org/article/e5376bbfd6944675a9c483362a1be0bc
Publikováno v:
Thoracic Cancer, Vol 15, Iss 23, Pp 1757-1763 (2024)
Abstract Background Epidermal growth factor receptor (EGFR) mutations are key drivers in a significant portion of non‐small‐cell lung cancer (NSCLC) patients. While third‐generation EGFR‐tyrosine kinase inhibitors (TKIs) such as osimertinib h
Externí odkaz:
https://doaj.org/article/a723a07ac722459eaa7b4f28f3ca4fe7
Autor:
Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii
Publikováno v:
Thoracic Cancer, Vol 15, Iss 23, Pp 1772-1775 (2024)
Abstract We present the case of a 34‐year‐old Japanese man with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, t
Externí odkaz:
https://doaj.org/article/9dda332cfb6e4c8c9d4fe688ccdf5463
Autor:
I. M. Horstman, P. C. Vinke, E. Suazo‐Zepeda, T. J. N. Hiltermann, M. A. Heuvelmans, E. Corpeleijn, G. H. deBock
Publikováno v:
Thoracic Cancer, Vol 15, Iss 23, Pp 1764-1771 (2024)
Abstract Objectives Pretreatment biomarkers are needed to identify patients with non‐small‐cell lung cancer (NSCLC) likely to have worse survival. This ensures that only patients with a real chance of benefit receive immune checkpoint inhibitor (
Externí odkaz:
https://doaj.org/article/dbf5d2f74ba34f8f8e2c2581396efe26
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Savolitinib, a small molecule inhibitor, has gained approval as the inaugural medication in China that specifically targets MET kinase. Patients with advanced non-small cell lung cancer (NSCLC) who show MET exon 14 skipping now ha
Externí odkaz:
https://doaj.org/article/c1ed67c9be4d4924b4a9338bdfe29532
Autor:
Kazuki Yamagata, Masahiro Yanagawa, Akinori Hata, Ryo Ogawa, Noriko Kikuchi, Shuhei Doi, Keisuke Ninomiya, Yukiko Tokuda, Noriyuki Tomiyama
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract We examined the association between texture features using three-dimensional (3D) io-dine density histogram on delayed phase of dual-energy CT (DECT) and expression of programmed death-ligand 1 (PD-L1) using immunostaining methods in non-sma
Externí odkaz:
https://doaj.org/article/f910323114a94c35aa049304248c3efd
Autor:
Jing Zhang, Pei-Yuan Lv, Xiao Zhao, Ming-Lu Liu, Lu-Peng Qiu, Zi-Zhong Yang, Sheng-Jie Sun, Guo-Qing Zhang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background This study aimed to evaluate the effectiveness and safety of recombinant human endostatin (Rh-endostatin) plus programmed cell death 1 (PD-1) inhibitors and chemotherapy as first-line treatment for advanced or metastatic non-small
Externí odkaz:
https://doaj.org/article/5454b9a09a4d4af499f7dd40fb5f4407
Autor:
Zeliang Ma, Yunsong Liu, Yongxing Bao, Qian Liu, Xu Yang, Yu Men, Jianyang Wang, Lei Deng, Yirui Zhai, Chen Hu, Nan Bi, Luhua Wang, Zhouguang Hui
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Introduction The estimated dose of radiation to immune cells (EDRIC) has been shown to correlate with the overall survival (OS) of patients who receive definitive thoracic radiotherapy. However, the planning target volume (PTV) may be a conf
Externí odkaz:
https://doaj.org/article/dbbe6ec2c1dd4eff956a06d93b9c412a
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Lung cancer is a leading cause of cancer-related death worldwide. Among various histological types of lung cancer, majority are non-small cell lung cancer (NSCLC) which account for > 80%. Circular RNAs (circRNAs) are widely expres
Externí odkaz:
https://doaj.org/article/dc9521684e4c4ed2a748f483efddf5c4
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Tucatinib (TUC), a HER2-directed tyrosine kinase inhibitor, is the first targeted drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic HER2-positive breast cancer (BC) patients with brain met
Externí odkaz:
https://doaj.org/article/9cf7e6b94efd4a4a95a977a74d3e3670